Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LON/0R02 stock hub

LON/0R02 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0R02is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0R02

In the news

Latest news · LON/0R02

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROE-51.1

P25 -54.2P50 2.1P75 13.7

ROIC-206.5

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0R02 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

164

Groups with data

Currency

USD

Showing 164 of 164 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	14
Employees Change	0%
Employees Change Percent	0
Enterprise value	$401,712
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biotechnology
Isin	US68620A3023
Last refreshed	2026-05-10
Market cap	$3M
Price	$0.26
Price currency	USD
Rev Per Employee	7,536.14x
Sector	Healthcare
Sic	2836
Symbol	lon/0R02
Website	https://vivosim.ai

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-30.88%
EV Earnings	-0.44x
EV/Sales	3.85x
P/B ratio	0.89x
P/S ratio	27.99x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-2.8M
Net Income	$-911,661
Net Income Growth Quarters	8%
Net Income Growth Years	2%
Pretax Margin	-862.68%
Profit Per Employee	$-65,119
ROA	-132.5
Roa5y	-46.48
ROCE	-255.4
ROE	-51.07
Roe5y	-70.04
ROIC	-206.5

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-97.91%
Cagr3y	-82.01%
Cagr5y	-74.49%
EPS Growth Quarters	2
EPS Growth Years	0
Revenue Growth	16.39x
Revenue Growth Q	8.33x
Revenue Growth Quarters	1x
Revenue Growth Years	1x
Revenue Growth3 Y	-56.36x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$5.2M
Cash	$3.2M
Current Assets	$4.4M
Current Liabilities	$1.8M
Debt	$603,316
Debt Equity	$0.18
Equity	$3.3M
Interest Coverage	-881.1
Liabilities	$1.9M
Long Term Assets	$740,122
Long Term Liabilities	$56,170
Net Cash	$2.6M
Net Cash By Market Cap	$87.47
Net Debt Equity	$-0.78
Tangible Book Value	$3.3M
Tangible Book Value Per Share	$1.27
WACC	8.92

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.44
Net Working Capital	$34,178
Quick ratio	1.75
Working Capital	$2.6M
Working Capital Turnover	$0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-84.51%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-97.9%
200-day SMA	10.99
3Y total return	-99.42%
50-day SMA	5.35
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.89%
All Time High	422.4
All Time High Change	-99.94%
All Time High Date	2018-05-22
All Time Low	0.26
All Time Low Change	1.34%
All Time Low Date	2025-03-20
ATR	1.26
Beta	1.13
Ch YTD	-94.87
High	0.28
High52	22.2
High52 Date	2025-02-26
High52ch	-98.81%
Low	0.26
Low52	0.26
Low52 Date	2025-03-20
Low52ch	0%
Ma50ch	-95.05%
Price vs 200-day SMA	-97.59%
RSI	38.65
RSI Monthly	30.53
RSI Weekly	35.28
Sharpe ratio	0.07x
Sortino ratio	0.2
Total Return	-84.51%
Tr YTD	-94.87
Tr1m	-94.04%
Tr1w	-94.74%
Tr3m	-93.66%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-8.5M
Operating margin	-8,066.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	2,581,213%
Net Borrowing	-180,444.4
Shares Insiders	10.82%
Shares Institutions	3.73%
Shares Qo Q	0.12%
Shares Yo Y	84.51%
Short Ratio	0.33

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	9,214.35x
Bv Per Share	1.27
Ch1m	-94.04
Ch1w	-94.74
Ch1y	-97.9
Ch3m	-93.66
Ch3y	-99.42
Ch5y	-99.89
Ch6m	-95.66
Change	2.08%
Change From Open	-0.23
Close	0.26
Days Gap	2.32
Depreciation Amortization	170,908.8
Dollar Volume	1,613.5
Earnings Date	2026-06-03
EBIT	$-8.5M
EBITDA	$-8.3M
EPS	$-0.39
F Score	3
Financing CF	3,529,250
Fiscal Year End	March
Founded	2,007
Income Tax	$1,486
Investing CF	6,687,743
Is Primary Listing	0
Last Earnings Date	2026-02-06
Last Report Date	2025-12-31
Last Split Date	2020-08-19
Last Split Type	Reverse
Ma150	8.46
Ma150ch	-96.87%
Ma20	6.32
Ma20ch	-95.81%
Net CF	2,323,361
Next Earnings Date	2026-06-03
Open	0.27
Position In Range	18.42
Ppne	567,006.3
Price Date	2025-03-20
Ptbv Ratio	0.89
Relative Volume	0.66x
Revenue	105,506x
SBC By Revenue	216.9x
Share Based Comp	228,844
Tax By Revenue	1.41x
Tr6m	-95.66%
Volume	6,100
Z Score	-73.88

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0R02 pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0R02 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0R02?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.7%

Share of float held by funds and institutions

Insider ownership

+10.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0R02 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.6

Neutral momentum band

Price vs 200-day MA

-97.6%

50/200-day relationship not available

Beta (5Y)

1.13

Moves roughly with the market

Sharpe ratio

0.07

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0R02

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0R02 stock rating?

lon/0R02 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0R02 analysis?

The full report lives at /stocks/lon/0R02/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0R02?

The latest report frames lon/0R02 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0R02 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.